BioSpace News Archive

Butterfly Network, Inc., a digital health company transforming care with handheld, whole-body ultrasound, announced financial results for the quarter ended March 31, 2022, and provided a business update.

Artiva Biotherapeutics, Inc. today announced the appointment of Edith A. Perez, M.D., as a member of the Company’s Board of Directors.

Mycovia Pharmaceuticals, Inc. will sponsor a product theater showcase for its recently FDA-approved VIVJOA™ (oteseconazole capsules), during the 2022 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting.

Metagenomi today announced that two presentations will be made at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, taking place virtually and in Washington, D.C., May 16-19, 2022.

Cybin Inc. today announced that an abstract highlighting preclinical data for its deuterated psilocybin analog CYB003 has been selected for a poster presentation at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicines taking place May 27-29, 2022.

9 Meters Biopharma, Inc. announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will present at the LifeSci Partners Immunology & Inflammation Symposium on May 10, 2022, and the H.C. Wainwright Global Investment Conference to be held on May 23-26, 2022.

Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), today announced the publication of a peer-reviewed manuscript that details an interim dataset of its ALIGN3D™ multicenter, prospective clinical study in the Journal of Foot & Ankle Surgery.

Sun Nuclear Corporation, a wholly-owned subsidiary of Mirion Technologies, Inc., will feature its comprehensive solutions portfolio for independent, integrated Quality Management of Radiation Therapy and Diagnostic Imaging at the ESTRO 2022 Congress, held May 6-10 in Copenhagen, Denmark.

Today, Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed’s lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential in a wide range of diseases driven by acute and chronic inflammation.

Moleculin Biotech, Inc. today announced that it has received allowance from the Polish Department of Registration of Medicinal Products (URPL), as well as the requisite Ethics Committee approval, to proceed with its Phase 1/2 clinical trial in Poland of Annamycin (L-ANN).